Risk management requirements for elemental impurities in veterinary medicinal products, including immunological veterinary medicinal products - Scientific guideline
Public statement on Esmya: Withdrawal of the marketing authorisation in the European Union
Comirnaty : Periodic safety update report assessment 19 June 2023 to 18 December 2023
Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 41, Status: Authorised
Guidance on the details of the classification of variations requiring assessment according to Article 62 of Regulation (EU) 2019/6 for veterinary medicinal products and on the documentation to be submitted pursuant to those variations
Compilation of Union procedures on inspections and exchange of information
Introduction to the Compilation of Union procedures on inspections and exchange of information
EMA recommends suspension of sickle cell disease medicine Oxbryta
Herbal medicinal product: Rosmarini foliumArray, F: Assessment finalised
Human medicines European public assessment report (EPAR): Optruma, raloxifene, Date of authorisation: 05/08/1998, Revision: 27, Status: Authorised